Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Plus Chemotherapy in Locally Advanced Gastric Cancer
NCT04250948Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2019
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in gastric cancer (GC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Tumor Regression Grade 0/1 at 12 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04250948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250948.